Novo Nordisk's ZEUS Failure Leaves the Danish Drugmaker Scrambling Ahead of Earnings
Published on 08/01/2026 at 21:02 | Redaktion boerse-global.de
The Danish pharmaceutical giant has been here before — a high-profile pipeline setback, a bruised share price, and a wall of questions from investors. But the fallout from Friday's collapse, when Novo Nordisk shares closed at €40.90 in Frankfurt after shedding 8.48 percent in a single session, feels different in kind, not just degree.
The trigger was unambiguous: Ziltivekimab, the company's experimental anti-inflammatory therapy, failed its pivotal Phase 3 trial. The ZEUS study enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers, all receiving monthly 15-milligram doses of the drug. While the treatment did what it was supposed to do biologically — suppressing the inflammatory markers IL-6 and hsCRP — it failed where it mattered clinically. The hazard ratio for the composite endpoint of cardiovascular death, heart attack, and stroke came in at 0.99, with a confidence interval of 0.88 to 1.11, a far cry from the 0.85 analysts had penciled in. Serious infections were also more frequent among patients taking the drug, though overall mortality showed no difference from placebo.
The setback carries an extra sting because of how Novo Nordisk acquired the asset. The company bought Ziltivekimab's developer, Corvidia, in 2020 for $725 million, betting that an inflammation-targeting approach could open a new front in cardiovascular prevention. Martin Holst Lange, the company's head of research and development, struck a diplomatic tone, insisting the results offered valuable scientific insights for ongoing work. But the strategic reality is harsher. JPMorgan analysts were blunt: with ZEUS failing, a potential billion-dollar blockbuster has evaporated. That matters all the more because the company had positioned the inflammation program as a hedge against its overwhelming reliance on diabetes and obesity drugs — a segment that still accounts for roughly 94 percent of group revenue.
The company is keeping its two remaining cardiovascular studies, HERMES and ARTEMIS, running as planned, with results expected in the first half of 2027. Management also confirmed that a non-cash impairment charge will hit the third quarter of 2026, though the full-year guidance for that year remains untouched.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Friday's rout, however, was never just about one trial. The sell-off rippled through the broader biotech sector, with investors questioning whether hsCRP works as a reliable predictor of clinical benefit. Monte Rosa Therapeutics bore the brunt, tumbling 27.5 percent, while BioAge Labs, Neurocrine, and Neumora also slid.
For Novo Nordisk shareholders, the ZEUS failure compounds two other headaches that surfaced in the same week. In the United States, a federal judge in Trenton, New Jersey, allowed parts of a shareholder lawsuit to proceed against the company. The litigation centers on CagriSema, the obesity candidate, and allegations that Novo Nordisk misled investors about its tolerability. The case draws on the REDEFINE-1 study from December 2024, in which participants achieved a 22.7 percent weight loss after 68 weeks — short of the 25 percent target. Only 57 percent of participants reached the highest dose, a fact plaintiffs argue was improperly withheld. The court dismissed other claims, and Novo Nordisk continues to deny the remaining allegations.
Then there is the core business itself, which is showing signs of fatigue. Citi analyst Graham Parry described the Wegovy franchise as essentially flat week over week, while Eli Lilly's competing oral pill advanced 16 percent in the same period. US weekly prescription data for the Wegovy pill hovered around 110,600, barely changed from the prior week. To be sure, cumulative prescriptions have now crossed the three-million mark in the US since the start of the year, but the growth trajectory has clearly flattened.
The technical picture offers little comfort. Novo Nordisk shares sit about 1.35 percent above their 200-day moving average, suggesting the longer-term trend hasn't fully broken down. But the stock now trades 25.45 percent below its 52-week high of €54.86 from January, and the RSI reading of 41.8 points to neither oversold conditions nor an imminent bounce.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Analysts are split on what comes next. Jefferies and Citi both called Friday's market reaction overdone, even as they acknowledged the strategic damage. Others note the valuation has become compelling: with a price-to-earnings ratio around 11, near multi-year lows, some see a buying opportunity in a company still positioned in a growing global GLP-1 market.
All of this converges on a single date: August 5, when Novo Nordisk reports its first-half results. The company's ability to steady the ship will depend heavily on how convincingly management can articulate a diversification strategy that no longer includes its former great hope. For now, the stock remains battered, the calendar is unforgiving, and the questions are stacking up faster than the answers.
Ad
Novo Nordisk Stock: New Analysis - 1 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
